| Patient | Johnny Cash |
|---|---|
| Date of birth | 1932-02-26 |
| Identifiers | MRN HR-ML004-SYN-TD; SSN (made up) 000-04-8125 |
| Document date | 2003-03-27 |
| Author | Gideon Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Endocrinology consultation and four-week diabetes check: lightheadedness on standing and choice of add-on glucose-lowering therapy. [S]
Mr. Cash is a 71-year-old man with type 2 diabetes, autonomic and peripheral neuropathy, and severe primary open-angle glaucoma, seen four weeks after his first visit for an endocrinology consultation on the same day as his diabetes check. Metformin was raised to 1000 mg twice daily, atorvastatin was started, and dorzolamide was added to latanoprost four weeks ago. He takes all of them, and metformin causes no stomach upset. His fasting home glucose readings run 140 to 170 mg/dL, with none below 70. He now stands up in stages, has raised the head of his bed, wears waist-high compression, and drinks about 2 liters a day. He is still lightheaded on standing most mornings and after meals, but he has had no further falls since the first visit. He asks again what he really has, since he was once told it was Shy-Drager syndrome. [S]
| Element | Detail |
|---|---|
| Interval change | Lightheaded on standing most mornings and after meals; no further falls |
| Medication tolerance | No stomach upset on metformin 1000 mg twice daily; no muscle aches on atorvastatin; no eye stinging on dorzolamide |
| Home glucose | Fasting 140 to 170 mg/dL; none below 70 |
| Non-drug measures | Staged standing, head of bed raised, waist-high compression, 2 liters of fluid a day |
| Patient question | What is causing the lightheadedness |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 1 kg; no fever |
| Cardiovascular | Positive | Lightheaded on standing, worse in the morning and after meals; no fainting, chest pain, or palpitations |
| Gastrointestinal | Negative | No nausea, diarrhea, or early fullness |
| Genitourinary | Negative | No difficulty passing urine |
| Neurological | Positive | Numb feet to the ankles, unchanged; weak legs |
| Endocrine | Negative | No shakiness, sweating, or confusion suggesting low glucose |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 500 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2001-05-06 to 2003-02-27 | completed | S |
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2003-02-27 | active | S |
| Sitagliptin 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2003-03-27 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2003-02-27 | active | S |
| Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime | One drop in each eye at bedtime | Ophthalmic route | 2000-09-11 | active | S |
| Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily | One drop in each eye twice daily | Ophthalmic route | 2003-02-27 | active | S |
| Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM | One tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bed | Oral route | 2003-03-27 to 2003-05-29 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2003-03-27 | Body height | 188 | cm | S |
| 2003-03-27 | Body weight | 95 | kg | S |
| 2003-03-27 | Body mass index (BMI) [Ratio] | 26.9 | kg/m2 | S |
| 2003-03-27 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2003-03-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2003-03-27 | Heart rate | 76 | /min | S |
| 2003-03-27 | Respiratory rate | 16 | /min | S |
| 2003-03-27 | Body temperature | 36.6 | Cel | S |
| 2003-03-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2003-03-27 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2003-03-27 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2003-03-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2003-03-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1998)/1.73 sq M | 72 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2003-03-27 | Glucose [Mass/volume] in Serum or Plasma | 152 | mg/dL | 70-99 mg/dL | High | S |
Vital signs recorded on 2003-03-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and wry; walks in with a cane |
| Cardiovascular | Regular rhythm; blood pressure 150/84 mmHg lying, 142/78 mmHg seated, and 110/68 mmHg after three minutes standing, with heart rate 76 rising only to 80, and lightheadedness |
| Feet | Skin intact; no ulcers or calluses; monofilament and vibration sensation reduced to the ankles; pedal pulses present |
| Neurological | Reduced ankle reflexes; stocking sensory loss in both legs |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intake | active | confirmed | E11.43 | S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy. |
| Neurogenic orthostatic hypotension from diabetic autonomic neuropathy | active | confirmed | I95.1 | S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome. |
| Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feet | active | confirmed | E11.42 | S — Synthetic finding linked to his description of numb lower extremities. |
| Primary open-angle glaucoma, both eyes, severe stage | active | confirmed | H40.1133 | S — Synthetic modern diagnosis; the type and stage are not documented historically. |
| Mild nonproliferative diabetic retinopathy without macular edema, both eyes | active | confirmed | E11.3293 | S — Synthetic finding from the dilated eye examination. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| History of recurrent pneumonia | active | confirmed | Z87.01 | S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | Before choosing add-on therapy; yearly when eGFR is 60 or more | Completed today | eGFR 72 and potassium 4.3: no dose change needed for metformin or sitagliptin, and safe to start midodrine |
| Laboratory | HbA1c | Every 3 months until at goal or after a therapy change; every 6 months when stable | Up to date | 8.6% four weeks ago; next at the three-month review |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after a statin starts or changes | Due | Atorvastatin started four weeks ago; draw within the next eight weeks |
| Examination | Blood pressure, weight, and BMI | Every visit | Completed today | Seated 142/78 mmHg; weight 95.0 kg, down 1 kg |
| Examination | Lying, seated, and standing blood pressure | Every visit | Completed today | Lying 150/84, standing 110/68 mmHg; heart rate 76 to 80. Baseline before midodrine |
| Examination | Foot examination (inspection, pulses, monofilament) | Every visit with loss of protective sensation | Completed today | No ulcer; sensory loss unchanged |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; 4 to 6 weeks after adding a drop | Deferred | Not measured at this visit, and no eye-clinic check has been booked since dorzolamide was added four weeks ago, a deviation from the plan. Request sent to the eye clinic |
| Survey | Hypoglycemia review and home glucose log | Every visit | Completed today | No readings below 70 mg/dL and no symptoms of low glucose |
| Survey | Tobacco use | Every visit | Completed today | No tobacco use |
| Medication safety | Metformin, atorvastatin, and dorzolamide tolerance | After each start or dose change | Completed today | No stomach upset, muscle aches, or eye stinging |
| Medication safety | Antihypertensive and other medicines that lower standing pressure | Every visit with orthostatic hypotension | Completed today | None in use; timolol and brimonidine avoided |
| Referral | Endocrinology consultation | When the diagnosis or treatment of a complication is uncertain | Completed today | Seen today: diabetic autonomic neuropathy confirmed as the working diagnosis, sitagliptin and midodrine started |
| Self-management | Orthostatic hypotension measures and foot self-care | Every visit | Completed today | Staged standing, head-of-bed elevation, compression, fluids, and daily foot checks reviewed |
Goal progress:
Guideline basis: Standards of Care in Diabetes—2025 (2025); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026)
Follow-up: Annual wellness visit in four weeks. Three-month review with HbA1c, lipids, and an eye pressure check. Next scheduled visit 2003-04-24: subsequent annual wellness visit. [S]